The subject received any investigational treatment within the past  days or prior immunotherapy or antibody therapy within the past  days.
History of hospitalization in past  months for diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic nonketotic syndrome (HHNS)
Relapse of pneumocystis carinii pneumonia within the past year before enrollment
Patients may not have received cabazitaxel in the past
Received PDT during the past  months
Patients must be at least  days past their last course of lymphoma or CLL treatment, at least  days past their last course of rituximab treatment. Patients with pre-existing severe or life threatening side effects/conditions from prior therapy or due to other diseases may not be enrolled
Has received any systemic bone-seeking radiopharmaceutical in the past
History of coronary or vascular stent placed within the past  months (may be extended to  year if medically indicated per physician discretion).
Carcinoma in situ (CIS) in the past in the urinary tract.
No increase in steroid dose within the past  days
Elevated urinary or plasma PBG or ALA values within the past year,
Significant clinical change in health in the past  days
Systemic antineoplastic therapy in the past  days (excluding hydroxyurea)
Participants have had at least  episode of vaso-occlusive crisis (VOC) in the past  months.
More than  VOCs within the past  months that required a hospital, emergency room or clinic visit
Currently on a leukotriene inhibitor or used within the past  months
Needing medical attention for serious bleeding in past  weeks
Patients with solid organ malignancy who have received chemotherapy within the past six months
Taxane therapy within the past  months ( days) prior to study day 
Subject has a positive serum Yo antibody (does not need to be repeated if performed in the past)
Patients with clinically significant cardiovascular disease: history of ischemic or hemorrhagic stroke within past  months; uncontrolled hypertension, on at least  repeated determinations on separate days within past  months; myocardial infarction or unstable angina within past  months; New York Heart Association grade III or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris within past  months; clinically significant peripheral vascular disease within past  months; pulmonary embolism, deep vein thrombosis (DVT), or other thromboembolic event within past  months; diagnosed congenital long QT syndrome; any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes); prolonged QTc interval on pre-entry electrocardiogram (>  msec); subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration
Serious or unstable disease within the past  months
Tumor staging by standard imaging within the past  days (Step  subjects only)
Subject has received chemotherapy within the past  days
Erythropoietin or related hormones must not have been administered within the past  days
Documented cerebral infarction within past  months
A prior history of Gliadel implantation in the past six months
Current or past history of cardiovascular disease (e.g.. past history of myocardial infarction, ischemic cardiomyopathy) unless cardiology consultation and clearance has been obtained for study participation
Patient with history of cardiac arrest within the past  months
A history of syncope with calorie restriction in the past or other medical comorbidity, which would make fasting potentially dangerous
A serious, unstable illness, as judged by the Investigator, during the past  months before screening/baseline visit including but not limited to: hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease;
History of chronic steroid use within the past  months
Use of treatments in the past  months that can affect VMS (e.g., use of oral or transdermal hormone therapy [HT] or contraceptives)
Prior cell therapy for relapse within the past  days
known or suspected past hepatitis C infection (including patients with past interferon 'curative' treatment),
Positive urine tetrahydrocannabinol (THC) dipstick test (> ng/mL; indicating marijuana use in the past - hours)
Regular or sporadic use of nicotine cigarettes (>  cigarettes in the past  days)
History of any one or more of the following cardiovascular conditions within the past  months:
No increase in steroid dose within the past  days
Subject has a history of seizure within the past  months of Screening as assessed by neurology examination and history.
History of suicide attempt or preparation for attempt within the past  years
CML treatment resistant mutation(s) (TI, EK/V, YH, FC/V) detected if a testing was done in the past (there is no requirement to perform mutation testing at study entry if it was not done in the past)
Dose reductions due to neutropenia or thrombocytopenia in the past  months
Prior/concurrent therapy including:\r\n* Tamoxifen, raloxifene, letrozole, anastrozole, or exemestane in the past  months\r\n* Chemotherapy, biologic therapy (e.g., trastuzumab [Herceptin]), or breast radiotherapy to the breast currently affected by DCIS within the past  months\r\n* Any exogenous hormonal therapy including estrogen-, progesterone-, and/or androgen-based agents in the past  months\r\n* Phytoestrogens or over-the-counter (OTC) medications with estrogenic or androgenic properties in the past  months\r\n* Any black cohosh preparation within the past  months
History of symptomatic genitourinary stones within the past year
Prior surgical endoscopic intervention within the past six months for Spigelman Stage  or  that may have been down staged to Spigelman  or .
Patients with a serious cardiac condition within the past  months
The donor has had: () a trauma or surgery in the past  months
Use of oral bisphosphonates within the past  year
Significant circulatory disorders in the past  months
History of certain cardiovascular conditions within the past  months.
Stable steroid dose in past  weeks
History of epistaxis requiring medical/surgical intervention (such as nasal packing) within the past  months
Important cardiovascular events in the past  months.
Subjects who have experienced a serious adverse event associated with an RBCx procedure in the past.
They have received treatment with orteronel or another lyase inhibitor in the past
Patients who have undergone radiation within the past  weeks
Prior invasive malignancy other than LACC diagnosed within the past  months, excluding anal intraepithelial neoplasia, non-melanoma skin carcinoma, or Kaposis sarcoma that has not required systemic chemotherapy within the past  months
Patients may not have had more than  days of treatment with ketoconazole by mouth in the past  months
History of certain cardiovascular conditions within the past  months.
Gliadel wafer or wafers implanted within the past  weeks
any investigational treatment within the past  days
History of prior treatment with chloroquine for malaria within past  months.
Smoked an average of less than  cigarettes per day during past month
No recent history (=<  days) of substance abuse (outside of tobacco) defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) as:\r\n* If male, drinking >  alcoholic beverages per week for past  month\r\n* If female, drinking >  alcoholic beverages per week for past  month\r\n* Use of cocaine, heroin, club drugs (i.e., ,-methylenedioxymethamphetamine (MDMA)/ecstasy), methamphetamine, or hallucinogens (e.g., lysergic acid diethylamide [LSD]) at any time during the past  month\r\n* Use of marijuana on a weekly basis for the past  month
Neutropenia (absolute neutrophil count < . x ^/L) at the time of study enrollment (bloodwork is not required if patient did not have chemotherapy within past  weeks).
Severe psychological impairment (e.g., hospitalization for depressive episode in the past  months)
Intractable seizures while on adequate anticonvulsant therapymore than  seizure per week for the past  months
Have not experienced a weight reduction >= % within past  months
Treated with chemotherapy within the past  months
Subject has received chemotherapy within the past  weeks
Severe psychological impairment (e.g., hospitalization for depressive episode in the past  months)
Patients will also be excluded if they report lower extremity (LE) surgery or injury to the LE in the past  months or a past medical history of primary hyperparathyroidism; or rhabdomyolysis
Chronic treatment with any inhaled steroid for >  month in past three months
Treatment with montelukast or zafirukast for >  month in past three months
Treatment with systemic steroids for >  month in past three months
Chronic nausea over the past  weeks
Average nausea numeric rating scale >= / over past  hours at screening
PATIENTS: On scheduled haloperidol for delirium (=<  mg in the past  h)or rescue haloperidol of >=  mg for restlessness/agitation in the past  h
Subjects who have had radiation to one or both breasts in the past
Current or past (<  months) engagement in PCST for cancer
Phase II: Patients with MBC who\r\n* Have been diagnosed with leptomeningeal disease in the past eight weeks\r\n* Have diagnosed with progressive brain metastases after initial radiation therapy in the past eight weeks\r\n* Have been diagnosed brain metastases and began whole brain radiation therapy in the past eight weeks\r\n* Have an unplanned hospital admission and be discharged within the past eight weeks\r\n* Have been diagnosed with triple negative breast cancer and started second-line therapy within the past eight weeks\r\n* Have received at least three different therapy regimens within a twelve month period and began the third-line therapy regimen within the past eight weeks\r\n* Have HER+ disease and started third-line therapy in the past eight weeks; or\r\n* Have estrogen receptor positive (ER+) disease and started third line chemotherapy in the past eight weeks\r\n* Have begun a treatment clinical trial in the past eight weeks
History of incontinence defined as any pad use for urinary leakage in the past  months
Reports a fall in the past  days
Undergone laser corrective eye surgery in the past  days
Current and past history of hypertension
Known cardiovascular disease, uncontrolled hypertension, or new cardiac event within the past  months
Have not received chemotherapy in the past  months
Current or past (<  months) engagement in PCST for cancer
Intractable seizures while on adequate anticonvulsant therapymore than  seizure per month for the past  months
Past participation in an MBCT group
Reports a fall in the past  days
Past participation in ACT or formal mindfulness training, and
Past history of sexual abuse
Hospitalized for psychiatric reasons within the past  months
Active yoga practice within the past  months
On regular doses of benzodiazepine or chlorpromazine within the past  hours
Cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
Patients who have taken melatonin within the past two weeks
Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy in the past  months
Participants must have been in their spousal relationship for at least the past  year
Tuberculosis requiring treatment within the past  years; all patients must have a negative quantiferon test within  weeks prior to starting study drug
Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy in the past  months
Use of venlafaxine or hypnosis in the past  months
Prior treatment with finasteride or dutasteride in the past  months
Patient must have completed curative chemotherapy within past  days at a Childrens Oncology Group (COG) institution
Chronic, current or recent (within the past three months) use of leukotriene antagonists
WHITE, NON-HISPANIC: Participants having had a skin examination within the past year.
H/L: Participants having had a skin examination within the past year.
Subjects taking long-term systemic steroids defined as greater than  months in the past  months
PHASE I: Use of IT at least  times in the past year
SOCIAL MEDIA STUDY: Use of IT at least  times in the past year to be consistent with the proposed intervention criteria
Smokes a minimum of  cigarettes per day over the past year.
Not have gardened in the past  gardening seasons
Recent quitters (have not smoked in past  days)
Use of chemotherapy, trastuzumab, or pertuzumab within the past  weeks
Use of laxatives within the past  days
Use of antibiotics within the past  days
Medications:\r\n* Current anticoagulant use (must discontinue for  weeks prior to fine needle aspirate [FNA])\r\n* Taking systemic hormones within two months (eight weeks) prior to screening RPFNA\r\n* Taken tamoxifen, raloxifene, or an aromatase inhibitor within the past  months\r\n* Participation on any chemoprevention trial within  months
Have smoked cigarettes or used any other tobacco product in the past  days (i.e., pipe, cigar) and unwilling to stop use for the study period
Smoke on >=  days of the past  days
A cardiovascular event in the past month
Participants must not have used any tobacco product in the past year
PILOT III: Has experienced fatigue within the past seven days
Serious or unstable disease within the past  months
Prior tamoxifen or raloxifene use in the past  year.
For Chantix:\r\n* Pregnant or breast feeding or planning to become pregnant in the next  months\r\n* Currently using nicotine replacement therapy (NRT)\r\n* History of suicide attempt in the past  months\r\n* History of thoughts of suicide in the past  months\r\n* History of thoughts of harming others in the past  months
Smoke one or more cigarettes on  out of the past  days
Participants who have had any immunomodulatory treatment in the past  months will be excluded
Not have gardened in the past  gardening seasons
Smoke cigarettes  of the past  days (not including days spent in the hospital)
STUDY II: Using e-cigarettes at least once per week over the past month
No change in menstrual patterns for the past  months preceding the time of registration
Zero CPD for past  weeks
 or more CPD for at least  out of past  months
Current smoker (>  cigarettes per day for the past  months)
Smoked regularly in the past year
Chronic, current or recent (within the past three months) use of leukotriene antagonists
Chronic, current or recent (within the past three months) use of glucocorticoids (systemic, topical and/or nasal sprays)
Smoke on >=  days of the past  days
Patients with positive findings on prior imaging within the past  weeks are eligible
For traditional cigarettes (TC) smokers, daily TC smoking in the past  months, at least  cigarettes per day, with no EC exposure in the past  months
For electronic cigarettes (EC) users, daily EC use in the past  months, at least  sessions per day, with no TC exposure in the past  months
No anti-estrogen therapy for desmoid tumor within the past  months
Subject has received a Feraheme (ferumoxytol) Injection within the past  months.
Prior diagnosis of asthma, OR use of an inhaler in past three years to treat or prevent bronchospasm
History of symptomatic genitourinary stones within the past year
Major changes in eating habits within the past  months
Other tobacco use within the past year for  consecutive days or  times
Postmenopausal (no menstrual cycle in the past  months)
Chemotherapy/radiation within the past year
Report tobacco use within the past  days
Have resided (and intend to continue to reside) in the same home as the child/ren for the past  months (and the next  months)
Patients who have already done the ESAS in the past
recent history of cardiovascular distress (heart attack in past year; arrhythmia; uncontrolled hypertension)
History of parathyroid disorder or history or malignancy-associated hypercalcemia requiring therapy in the past  months
Participants must not have had chemotherapy within the past  days
Cancer treatment within the past  weeks
